HM
RCUS icon

HealthCor Management’s Arcus Biosciences RCUS Stock Holding History

HealthCor Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-70,050
Closed -$2.44M – 84
2021
Q3 		$2.44M Buy
+70,050
New +$2.18M 0.11% 56
2021
Q2 		– Sell
-536,970
Closed -$15.1M – 99
2021
Q1 		$15.1M Buy
+536,970
New +$18.7M 0.53% 48

Other funds holding RCUS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

HealthCor Management's RCUS Position: Q4 2021 in Review

HealthCor Management sold out of Arcus Biosciences (RCUS) in Q4 2021, closing a stake of 70,050 shares — an estimated $2.44M sold.

HealthCor Management first reported a position in RCUS in Q1 2021 and held it in 2 quarters. The position peaked at $15.1M in Q1 2021. 142 funds tracked by Wall St. Rank hold RCUS as of Q4 2021.

  • HealthCor Management reported no remaining Arcus Biosciences position as of Q4 2021 after selling out during the quarter.
  • HealthCor Management sold 70,050 Arcus Biosciences shares in Q4 2021, an estimated $2.44M.
  • HealthCor Management first reported a position in Arcus Biosciences in Q1 2021 and held it in 2 quarters.
  • HealthCor Management's Arcus Biosciences position peaked at $15.1M in Q1 2021.
  • 142 funds tracked by Wall St. Rank held Arcus Biosciences as of Q4 2021.

Based on HealthCor Management's 13F filing for Q4 2021, filed 14 Feb 2022.